Figure 1 Generations of cancer vaccine antigens

Slides:

Advertisements

Similar presentations

Figure 1 Estimated annual percentages of new

Advertisements

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 1 Key elements of cancer-related inflammation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 The mechanistic link between the epithelial-to-mesenchymal

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Neoantigen presentation in the tumour microenvironment

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Chimeric antigen receptor (CAR) structures

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Figure 2 Peptide vaccination using TAA-derived long peptides

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 Balance between proteasomal load and capacity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 3 The yin and yang of tumour-associated

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Figure 2 The patterns of epithelial-to-mesenchymal

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 5 Palliative-care-referral patterns

Figure 2 Dominance of the cell-extrinsic effects of autophagy

Figure 2 Frequency and overlap of alterations

Figure 2 Logistical requirements for autologous

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Chung-Han Lee, Roman Yelensky, Karin Jooss, Timothy A. Chan

Figure 1 Mechanisms of action of immunotherapy modalities

Figure 2 Effect of chromosomal instability tolerance

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Figure 1 Gene-expression quantification methods

Presentation transcript:

Figure 1 Generations of cancer vaccine antigens Figure 1 | Generations of cancer vaccine antigens. Early clinical studies used whole cancer cell preparations (for example, tumour lysates) as the source of tumour antigens, comprising a mixture of self-antigens and undefined neoantigens. These vaccines elicited broad immune responses, possibly not reaching a critical threshold for the frequency of anticancer T cells needed for clinical efficacy. The next stage of cancer vaccine development was focused on purified self-antigens, the use of which requires breaking of T-cell tolerance. Most recently, defined neoantigens have been pursued as drivers of a focused immune response that enables the critical thresholds for the frequency of anticancer T cells and clinical efficacy to be reached. Banchereau, J. & Palucka, K. (2017) Cancer vaccines on the move Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.149